triple-negative breast cancer

1 curated biomarker

← Back to browse

FDA-approved treatments

PD-L1
- Tecentriq (atezolizumab) [fda]
- Imfinzi (durvalumab) [fda]
- Opdivo (nivolumab) [fda]
- Keytruda (pembrolizumab) [ema]

Prevalence

PD-L1
PD-L1 expression thresholds and prevalence vary substantially by tumor type and assay; high PD-L1 expression (TPS >= 50%) is seen in approximately 25%-30% of NSCLC by validated companion diagnostic assays.[fda]

Tests / detection method

PD-L1
IHC

Therapeutic pipeline

PD-L1
- Next-generation immune checkpoint combinations (e.g., LAG-3, TIGIT co-blockade) (LAG-3 expression, TIGIT expression) [fda]

PubMed Central · Sep 2, 2026
Multi-omics integration uncovers epigenetic control of metabolic reprogramming in triple-negative breast cancer.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Sep 1, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.
- ERBB2 (biomarker)
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Sep 1, 2026
4-2 VHL-Recruiting PROTAC Inhibits the Growth and Migration of Triple Negative Breast Cancer Cells by Triggering Pyroptosis Through Fas-Mediated IL-17 Signaling.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Sep 1, 2026
Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.
- PD-L1 (biomarker)
Read at PubMed Central
PubMed Central · Aug 29, 2026
Programmed Death-Ligand 1 (PD-L1) expression and clinical outcomes in oral squamous cell carcinoma: evidence from a large clinical cohort.
- PD-L1 (biomarker)
Read at PubMed Central
PubMed Central · Aug 26, 2026
RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis.
Read at PubMed Central
PubMed Central · Aug 26, 2026
Current and future therapies for triple-negative breast cancer.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.
- PD-L1 (biomarker)
Read at PubMed Central
PubMed Central · Aug 25, 2026
Enhanced mitochondrial fission promotes chemosensitivity via SHP-1 activity in triple-negative breast cancer.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 25, 2026
[Preparation of HLYVSPW peptide-displaying outer membrane vesicles and validation of their in vitro targeting effects on triple-negative breast cancer cells].
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 24, 2026
Exome-based cancer driver gene comprehensive testing can provide a genetic diagnosis for individuals with triple-negative breast cancer.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 21, 2026
Glycolytic enolase 1-induced H4K12 lactylation activates quiescent breast cancer stem-like cells in triple-negative breast cancer.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 21, 2026
Durable response to olaparib plus continued PD-1 blockade in germline PALB2-mutated triple-negative breast cancer with leptomeningeal metastasis: A case report.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 20, 2026
[Overexpression of miR-183-5p enhances malignant phenotype and inhibits ferroptosis of triple-negative breast cancer cells by negatively regulating KLHL24].
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 20, 2026
Single-cell multiomics reveals exosome-mediated reprogramming and clonotypic remodeling of T cells in triple-negative breast cancer.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 20, 2026
[Prediction and verification of therapeutic drugs for triple-negative breast cancer using a knowledge graph-based drug repurposing model].
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 17, 2026
Optimizing immunotherapy-radiotherapy synergy in triple-negative breast cancer: mechanisms, clinical evidence, and therapeutic windows.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 17, 2026
CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 17, 2026
Spheroid cultures reveal cancer stem cell enrichment and distinct chemotherapeutic response in triple-negative breast cancer.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 15, 2026
Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor-positive and triple-negative breast cancer patients.
- breast cancer (tumour type)
Read at PubMed Central

triple-negative breast cancer

FDA-approved treatments

Prevalence

Tests / detection method

Therapeutic pipeline

Recent news for triple-negative breast cancer

Multi-omics integration uncovers epigenetic control of metabolic reprogramming in triple-negative breast cancer.

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

4-2 VHL-Recruiting PROTAC Inhibits the Growth and Migration of Triple Negative Breast Cancer Cells by Triggering Pyroptosis Through Fas-Mediated IL-17 Signaling.

Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.

Programmed Death-Ligand 1 (PD-L1) expression and clinical outcomes in oral squamous cell carcinoma: evidence from a large clinical cohort.

RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis.

Current and future therapies for triple-negative breast cancer.

Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.

Enhanced mitochondrial fission promotes chemosensitivity via SHP-1 activity in triple-negative breast cancer.

[Preparation of HLYVSPW peptide-displaying outer membrane vesicles and validation of their in vitro targeting effects on triple-negative breast cancer cells].

Exome-based cancer driver gene comprehensive testing can provide a genetic diagnosis for individuals with triple-negative breast cancer.

Glycolytic enolase 1-induced H4K12 lactylation activates quiescent breast cancer stem-like cells in triple-negative breast cancer.

Durable response to olaparib plus continued PD-1 blockade in germline PALB2-mutated triple-negative breast cancer with leptomeningeal metastasis: A case report.

[Overexpression of miR-183-5p enhances malignant phenotype and inhibits ferroptosis of triple-negative breast cancer cells by negatively regulating KLHL24].

Single-cell multiomics reveals exosome-mediated reprogramming and clonotypic remodeling of T cells in triple-negative breast cancer.

[Prediction and verification of therapeutic drugs for triple-negative breast cancer using a knowledge graph-based drug repurposing model].

Optimizing immunotherapy-radiotherapy synergy in triple-negative breast cancer: mechanisms, clinical evidence, and therapeutic windows.

CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer.

Spheroid cultures reveal cancer stem cell enrichment and distinct chemotherapeutic response in triple-negative breast cancer.

Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor-positive and triple-negative breast cancer patients.